Gynécologie - Colposcopie
Pathologies génitales à papillomavirus

Worldwide burden of cancer attributable to HPV by site, country and HPV type

Int. J. Cancer: 141, 664–670 (2017) VC 2017 International Agency for Research on Cancer (IARC/WHO); licensed by UICC

Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial

Gynecol Oncol (2015)

Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: systematic review and meta-analysis

International Journal of Cancer | doi: 10.1002/ijc.33035 (May 4,2020)

Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening

British Journal of Cancer https://doi.org/10.1038/s41416-020-0790-1 (April 3, 2020)

Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening

International Journal of Cancer | DOI: 10.1002/ijc.32973 (March 14, 2020)

Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening

International Journal of Cancer | DOI: 10.1002/ijc.32973, (March 1, 2020)

A Systematic Review of Tests for Postcolposcopy and Posttreatment Surveillance

Journal of Lower Genital Tract Disease Volume 24, Number April 2, 2020

2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation

Journal of Lower Genital Tract Disease  Volume 24, Number  April 2, 2020

A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines

Journal of Lower Genital Tract Disease  Volume 24, Number  April 2, 2020

Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months

JAMA. 2018;320(1):43-52. doi:10.1001/jama.2018.7464

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer

Ann Intern Med​ 2018 Jan 2;168(1):20-29 |  doi: 10.7326/M17-1609  

Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands

 BMJ 2016;355:i4924 | doi: 10.1136/BMJ.i4924

Le dépistage primaire par test HPV offre une plus grande protection (60-70%) contre le cancer invasif du col que le dépistage par frottis

The Lancet, 2014 ;383, 9916, 524 - 532

Le test HPV dans le dépistage du cancer du col utérin réduit de 70% le cancer invasif comparé au frottis

The Lancet, Vol. 383, No. 9916, p524–532 Published: November 3, 2013

HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study

The BMJ | BMJ 2010;340 |  doi : 10.1136/BMJ.c1040 

HPV Vaccination and the Risk of Invasive Cervical Cancer

The New England Journal of Medicine 383;14 nejm.org October 1, 2020

Design and content validation of a survey questionnaire assessing the determinants of human papillomavirus (HPV) vaccine hesitancy in France: A reactive Delphi study

Elsevier Vaccine. 2020 Jul 25;S0264-410X(20)30943-9 | doi: 10.1016/j.vaccine.2020.07.027.

Vaccination  HPV universelle, garçons et filles 

Recommandations Haute Autorité de Santé (HAS décembre 2019)

Pour un dépistage et une vaccination unvierselle contre la papillomavirus

Appel des 50 : Académies, Collèges, Socités et Syndicaux médicaux

Communiqué de presse  20 mars 2019

Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancerin 181 countries, 2020-99 : a modelling study

www.thelancet.com - Published online February 19, 2019

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15–26 Years of Age

2018 by the American College of Obstetricians and Gynecologists

Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017±2035: Example from Australia

 PLOS ONE | https://doi.org/10.1371/journal.pone.0185332 February 14, 2018

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

www.thelancet.com - Published online September 5, 2017

Nine-valent human papillomavirus vaccine: great science, but will it save lives?

www.thelancet.com - Published online September 5, 2017

Vaccination contre les infections à HPV et risque de maladies autoimmunes : une étude Cnamts/ANSM rassurante - Point d'information

ANSM/CNAMTS (13/09/2015)

Vaccins anti-HPV et risque de maladies autoimmunes : étude pharmacoépidémiologique

ANSM/CNAMTS (Rapport final, septembre 2015)

No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England

Vaccine (2017) 1729-1732 - Copyright 2017 Published by Elsevier Ltd.

Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs

Journal of Infectious Diseases Advance Access published (July 30, 2015)

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

The New England Journal of Medicine 372;8 nejm.org (February 19, 2015)

Safety of human papillomavirus vaccines: a review

Expert Opin. Drug Saf. (2015) 14(5) (February 24, 2015)

Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other Demyelinating Diseases of the Central Nervous System

JAMA. 2015;313(1):54-61 | doi:10.1001/jama.2014.16946 (January 6, 2015)

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia

BMJ 2014;348:g1458 doi: 10.1136/bmj.g1458 (March 4,2014)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

JAMA January 6, 2015 Volume 313, Number 1

Safety of human papillomavirus vaccines: a review

Expert Opin. Drug Saf. (2015) 14(5) 

HPV “Coverage”

N. Engl J Med 372;8 nejm.org february 19, 2015  

The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon

BMJ 2014;348:g1458 doi: 10.1136/Expert Rev. Vaccines Early online, 1–12 (2014)

Avis d’experts (Europe et Australie)

Décembre 2013

Profil de sécurité des vaccins HPV, faut-il s'en inquiéter ?

Génésis - N°177 Février/mars 2014

Safety of Human Papillomavirus Vaccines: A Review

Springer International Publishing Switzerland 2013

Vaccins HPV : que font nos autorités de santé face à la crise ?

(12 décembre 2013, Le Quotidien du Médecin)

Prévention du cancer du col utérin (II) : vaccination HPV prophylactique, connaissances actuelles, modalités pratiques et nouveaux enjeux

Presse Med. 007; 36: 640 - 2007 Elsevier Masson

Prévention du cancer du col utérin (I) : apport du dépistage, récents progrès et perspectives

Presse Med. 2007; 36: 92-111 - 2006 Elsevier Masson

Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer

(Annals of Oncology 00: 1–5, 2017)

Cunnilingus et cancer de la gorge : Michael Douglas dit vrai, mais pas d'inquiétude

(4 juin 2013, Le Nouvel Observateur)

Que penser du lien établi par Michael Douglas entre sexe oral et cancer de la gorge : l’avis du spécialiste français du papillomavirus - Atlantico

Que penser du lien établi par Michael Douglas entre sexe oral et cancer de la gorge : l’avis du spécialiste français du papillomavirus - Atlantico

HPV en gynécologie, nouvelles pratiques en marche

GENESIS - N° 204 - Décembre 2020

Infection à HPV, 25 années de recherche 

GENESIS - N° 192 - Novembre/Décembre 2016